[go: up one dir, main page]

MX2017008277A - Solucion oftalmica acuosa. - Google Patents

Solucion oftalmica acuosa.

Info

Publication number
MX2017008277A
MX2017008277A MX2017008277A MX2017008277A MX2017008277A MX 2017008277 A MX2017008277 A MX 2017008277A MX 2017008277 A MX2017008277 A MX 2017008277A MX 2017008277 A MX2017008277 A MX 2017008277A MX 2017008277 A MX2017008277 A MX 2017008277A
Authority
MX
Mexico
Prior art keywords
ophthalmic solution
aqueous ophthalmic
concentration
aqueous
diquafosol
Prior art date
Application number
MX2017008277A
Other languages
English (en)
Other versions
MX384935B (es
Inventor
Inagaki Koji
Ogawa Toshihiro
Nakazawa Hitoshi
Matsumoto Naoki
Wakabayashi Yukihisa
Kamimura Asuka
Oshita Yoshihiro
Matsuoka Isao
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56150716&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017008277(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MX2017008277A publication Critical patent/MX2017008277A/es
Publication of MX384935B publication Critical patent/MX384935B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C13/00—Assembling; Repairing; Cleaning

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención se relaciona con una solución oftálmica acuosa que comprende diquafosol o una sal del mismo a una concentración del 0.1% al 10% (p/v) y una clorhexidina a una concentración del 0.0001% al 0.1% (p/v).
MX2017008277A 2014-12-25 2015-12-25 Solucion oftalmica acuosa. MX384935B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014263003 2014-12-25
JP2015114595 2015-06-05
PCT/JP2015/086230 WO2016104704A1 (ja) 2014-12-25 2015-12-25 水性点眼液

Publications (2)

Publication Number Publication Date
MX2017008277A true MX2017008277A (es) 2017-10-02
MX384935B MX384935B (es) 2025-03-14

Family

ID=56150716

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008277A MX384935B (es) 2014-12-25 2015-12-25 Solucion oftalmica acuosa.

Country Status (13)

Country Link
US (2) US10278985B2 (es)
JP (3) JP6779614B2 (es)
KR (3) KR102330736B1 (es)
AR (1) AR105199A1 (es)
BR (1) BR112017013841A2 (es)
CA (1) CA2971689C (es)
EA (1) EA034517B1 (es)
MX (1) MX384935B (es)
MY (1) MY182507A (es)
PH (1) PH12017501096A1 (es)
SG (1) SG11201705138QA (es)
TW (1) TWI709405B (es)
WO (1) WO2016104704A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY182507A (en) * 2014-12-25 2021-01-25 Santen Pharmaceutical Co Ltd Aqueous ophthalmic solution
WO2016195073A1 (ja) * 2015-06-05 2016-12-08 参天製薬株式会社 水性点眼液
EP3305301B1 (en) * 2015-06-05 2024-11-27 Santen Pharmaceutical Co., Ltd. Therapeutic agent for dry eye characterized by being to be dropped into eye of dry eye patient wearing soft contact lens
MX2020008925A (es) * 2018-02-28 2020-10-01 Santen Pharmaceutical Co Ltd Composicion oftalmica que comprende dicuafosol y polimero cationico.
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
US11229549B2 (en) * 2019-09-18 2022-01-25 Vance M. Thompson Tear transplantation and multi-part contact lens with absorbent portion
CA3176584A1 (en) * 2020-03-31 2021-10-07 Santen Pharmaceutical Co., Ltd. Silver salt-containing ophthalmic aqueous composition filled in resin container
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
WO2021261930A1 (ko) * 2020-06-23 2021-12-30 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP2022102757A (ja) * 2020-12-25 2022-07-07 ライオン株式会社 機械学習実行プログラム、ドライアイ検査プログラム、機械学習実行装置及びドライアイ検査装置
KR102548710B1 (ko) 2020-12-24 2023-06-28 주식회사 종근당 디쿠아포솔 또는 이의 약제학적으로 허용가능한 염과 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
JP7230169B2 (ja) * 2020-12-25 2023-02-28 参天製薬株式会社 ジクアホソルまたはその塩、銀塩およびイオン性等張化剤を含有する水性点眼液
WO2024010040A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09301858A (ja) 1996-05-13 1997-11-25 Senju Pharmaceut Co Ltd グルコン酸クロルヘキシジン安定化水性薬剤
JPH10203960A (ja) * 1997-01-24 1998-08-04 Ofutekusu:Kk 点眼液組成物
JPH1160505A (ja) 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd 防腐組成物
JP2008222638A (ja) 2007-03-13 2008-09-25 Teika Seiyaku Kk 油成分含有眼用組成物
JP2009073788A (ja) 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
JP5398452B2 (ja) * 2008-09-30 2014-01-29 大正製薬株式会社 点眼剤
JP5639409B2 (ja) * 2009-08-07 2014-12-10 ロート製薬株式会社 シリコーンハイドロゲルコンタクトレンズ用眼科組成物
JP6047272B2 (ja) * 2010-09-15 2016-12-21 テイカ製薬株式会社 角膜上皮障害治療用点眼剤
MY161032A (en) * 2010-12-28 2017-04-03 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
BR112014023402B1 (pt) 2012-03-26 2020-09-29 Santen Pharmaceutical Co., Ltd Solução oftálmica compreendendo diquafosol e métodos para produção da mesma, para inibição da formação dos precipitados insolúveis na mesma, para redução da irritação ocular causada pela mesma e para aumentar a eficácia de conservação da mesma
MY182507A (en) * 2014-12-25 2021-01-25 Santen Pharmaceutical Co Ltd Aqueous ophthalmic solution

Also Published As

Publication number Publication date
EA201791467A1 (ru) 2017-11-30
US20190209599A1 (en) 2019-07-11
JP2021008513A (ja) 2021-01-28
MY182507A (en) 2021-01-25
US20170348344A1 (en) 2017-12-07
CA2971689A1 (en) 2016-06-30
TW201628626A (zh) 2016-08-16
AR105199A1 (es) 2017-09-13
KR20170067900A (ko) 2017-06-16
KR101789019B1 (ko) 2017-10-20
BR112017013841A2 (pt) 2018-06-19
TWI709405B (zh) 2020-11-11
KR20170118255A (ko) 2017-10-24
JP2022166223A (ja) 2022-11-01
WO2016104704A1 (ja) 2016-06-30
JP7128243B2 (ja) 2022-08-30
PH12017501096A1 (en) 2017-11-27
MX384935B (es) 2025-03-14
JP6779614B2 (ja) 2020-11-04
SG11201705138QA (en) 2017-07-28
KR20180063381A (ko) 2018-06-11
KR102330736B1 (ko) 2021-11-23
JP2016210759A (ja) 2016-12-15
EA034517B1 (ru) 2020-02-17
CA2971689C (en) 2020-11-03
US10278985B2 (en) 2019-05-07
KR101867791B1 (ko) 2018-06-15
US10786526B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
MX2017008277A (es) Solucion oftalmica acuosa.
MX369921B (es) Tratamiento de la hgna y ehna.
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
EP3397675A4 (en) GELE AND NANO COMPOSITE WITH ANFS
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
MX2017015236A (es) Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
DOP2015000199A (es) Formas del metil {4,6-diamino-2- [1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
BR112016016274A2 (pt) Ponte da barreira hematoencefálica
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
EP3328379A4 (en) BIS-HETEROARYL DERIVATIVES AS MODULATORS OF THE PROTEIN AGGREGATION
MX368954B (es) Insectos modificados para reducir la expresion genica especifica en los testiculos para los metodos de control biologico.
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
MX2018004033A (es) Composicion acuosa que contiene dantroleno.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
PT3367795T (pt) Soluções microbicidas aquosas, que incluem uma monocloramina e um perácido, e métodos da sua utilização
BR112017008481A2 (pt) composto antimicótico
MX381252B (es) Virus de la enteritis del pato y usos del mismo.
AR104591A1 (es) Piroglutamato de vortioxetina